Clinical Trial Update: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of CPI-613 (devimistat) with cytarabine and mitoxantrone hydrochloride in relapsed or refractory acute myeloid leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Granulocytic Sarcoma

Drugs mentioned

• CPI-613 (devimistat) (devimistat)
• CYTARABINE (CYTARABINE)
• Mitoxantrone hydrochloride (mitoxantrone)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2024-09-19